Form 4: Neurocrine Director Exercises Options, Sells Shares

A Neurocrine Biosciences director exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• Leslie V Norwalk, a Director at Neurocrine Biosciences Inc. (NBIX), reported transactions on December 15 and December 16, 2025.
• On December 15, 2025, Norwalk exercised 8,276 Non-Qualified Stock Options at an exercise price of $92.35 per share.
• Also on December 15, 2025, Norwalk exercised an additional 1,724 Non-Qualified Stock Options at an exercise price of $84.95 per share.
• Following these exercises, Norwalk's direct beneficial ownership of common stock increased to 12,429 shares.
• On December 15, 2025, Norwalk sold 5,000 shares of common stock at a weighted average price of $152.2287 per share, with prices ranging from $151.79 to $152.82.
• On December 16, 2025, Norwalk sold an additional 1,190 shares of common stock at a weighted average price of $155.0911 per share, with prices ranging from $155.09 to $155.40.
• All dispositions were executed by a broker pursuant to a Rule 10b5-1 trading plan adopted by Norwalk on September 12, 2025.
• After all reported transactions, Norwalk's direct beneficial ownership of common stock stands at 6,239 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction report (Form 4) detailing option exercises and planned stock sales. It does not inherently convey positive or negative news about the company's operational or financial performance.

Positives

• The director exercised options at significantly lower prices ($92.35 and $84.95) compared to the sale prices ($152.2287 and $155.0911), indicating a profitable transaction for the insider.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing equity holdings rather than opportunistic selling based on non-public information.

Negatives

• The director sold a portion of their common stock holdings, which, while pre-planned, represents a reduction in direct equity exposure to the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape for Neurocrine Biosciences. It reflects an individual director's equity management strategy.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if pre-planned, slightly reduces insider ownership, which some investors might monitor. However, the overall impact is minimal given the routine nature and relatively small volume compared to the company's total outstanding shares.
• Employees, Customers, Suppliers, Creditors: No direct impact is expected from this insider transaction report.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Transaction, Stock Options, Rule 10b5-1 Plan, Director, Equity Sales